Rapid Dose Therapeutics Corp.

Equities

DOSE

CA75339A1012

Medical Equipment, Supplies & Distribution

Market Closed - Canadian Securities Exchange Other stock markets 09:00:05 25/06/2024 pm IST			5-day change	1st Jan Change
0.18 ^CAD	0.00%		-14.29%	+9.09%

29/05	Rapid Dose Therapeutics Commits to NFL-Funded Clinical Trial Application	MT
22/05	Rapid Dose Therapeutics Corp. and McMaster University's Incorporation of Loratadine-Cyclodextrin Complexes in Oral Thin Films for Rapid Drug Delivery	CI

Rapid Dose Therapeutics Corp. Reports Earnings Results for the Third Quarter Ended November 30, 2018

January 30, 2019 at 03:12 am IST

Rapid Dose Therapeutics Corp. announced earnings results for the third quarter ended November 30, 2018. For the third quarter, the company announced sales was CAD 2,206 compared to CAD 0 a year ago. Net loss was CAD 1.005 million compared to CAD 411,043 a year ago. Basic loss per share was CAD 0.02 compared to CAD 0.02 a year ago.

Latest news about Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics Commits to NFL-Funded Clinical Trial Application	29/05	MT
Rapid Dose Therapeutics Corp. and McMaster University's Incorporation of Loratadine-Cyclodextrin Complexes in Oral Thin Films for Rapid Drug Delivery	22/05	CI
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in funding	25/03	CI
Rapid Dose Therapeutics Corp. Appoints Angela O'Leary to the Board of Directors	08/02	CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023	30/01	CI
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 7.000001 million in funding	19/01	CI
Rapid Dose Therapeutics Corp. announced that it has received CAD 3.134445 million in funding	22/12	CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023	30/23/30	CI
Rapid Dose Therapeutics Corp. Announces the Resignation of Andrew Duckman from the Company's Board of Directors	23/23/23	CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the First Quarter Ended May 28, 2023	28/23/28	CI
Rapid Dose Therapeutics Narrows Fiscal Q4 Loss, Revenue Grows	29/23/29	MT
Rapid Dose Therapeutics Corp. Auditor Raises 'Going Concern' Doubt	28/23/28	CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the Full Year Ended February 28, 2023	28/23/28	CI
Rapid Dose Increased Proposed Private Placement Financing of Up to $5 Million; Gained 30% on Tuesday	14/23/14	MT
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 3 million in funding	02/23/02	CI
Rapid Dose Therapeutics Corp. Launches QuickStrip™ Dental Products in the Canadian Market	11/23/11	CI
Rapid Dose Therapeutics Corp. Announces Changes to Its Board of Directors	14/23/14	CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2022	30/23/30	CI
Rapid Dose Therapeutics Corp. Auditor Raises 'Going Concern' Doubt	27/23/27	CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the First Quarter Ended May 31, 2022	27/23/27	CI
Rapid Dose Therapeutics Brief: Says Co and its Auditors Continuing to work "diligently" to complete Audit of Annual financial statements for the fiscal year ended February 28, 2022	11/23/11	MT
Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order	30/22/30	MT
Rapid Dose Therapeutics Corp. Enters Supplier and Purchase Agreement with A Leading Gas and Convenience Store Retailer for Nutraceutical and Vitamin Products	23/22/23	CI
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 5 million in funding	26/22/26	CI
Rapid Dose Therapeutics Corp. announced a financing transaction	25/22/25	CI

Chart Rapid Dose Therapeutics Corp.

Duration

Period

More charts

Company Profile

Rapid Dose Therapeutics Corp. is a Canadian biotechnology company. The Company provides disruptive drug delivery technologies designed to improve patient outcomes. The Companyâs flagship product, QuickStrip, is a thin, orally dissolvable film that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals, and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. It offers over-the-counter and pharmaceutical drug delivery solutions. Its QuickStrip Energy delivers energizing caffeine. Its QuickStrip B12 delivers vitamin B12 to the system, assisting with metabolism and physical energy. Its QuickStrip Sleep delivers melatonin to the system, inducing natural and healthy sleep. QuickStrip Lidocaine is its dental product. The Company also provides production and consultation to the nutraceutical, cannabis healthcare and pharmaceutical manufacturing industries.

Sector

Medical Equipment, Supplies & Distribution

Calendar

30/07/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Drug Delivery Systems

	1st Jan change	Capi.
RAPID DOSE THERAPEUTICS CORP.	+9.09%	1.61Cr
SEDANA MEDICAL AB	+6.43%	23Cr

Drug Delivery Systems